SPi	Journal Code				Article ID				Dispatch: 00.00.00	CE:
	В	М	С		3	9	5	3	No. of Pages: 8	ME:

Revised: 20 January 2017

Received: 31 October 2016

DOI 10.1002/bmc.3953

1

2

3

4

5

6 7

8

9

10

11

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

 $Q2 \frac{12}{Q1}$

Accepted: 6 February 2017

The establishment of tocopherol reference intervals for

WILEY Biomedical Chromatography

87

88

89

90

91

92

93

RESEARCH ARTICLE

Hungarian adult population using a validated HPLC method Gábor Veres^{1,2} | László Szpisjak¹ | Attila Bajtai¹ | Andrea Siska³ | Péter Klivényi¹ | István Ilisz⁴ | Imre Földesi³ | László Vécsei^{1,2} | Dénes Zádori¹ ¹Department of Neurology, Faculty of Abstract Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary ²MTA-SZTE Neuroscience Research Group, Szeged, Hungary ³Department of Laboratory Medicine, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary ⁴Department of Inorganic and Analytical Chemistry, Faculty of Science and Informatics, University of Szeged, Szeged, Hungary Correspondence Dénes Zádori, Department of Neurology, Faculty of Medicine, Albert Szent-Györgvi Clinical Center, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary. Email: zadori.denes@med.u-szeged.hu Funding information János Bolyai Research Scholarship of the Hungarian Academy of SciencesHungarian Brain Research Program, Grant/Award Number: KTIA_13_NAP-A_II/18.

Evidence suggests that decreased α -tocopherol (the most biologically active substance in the vitamin E group) level can cause neurological symptoms, most likely ataxia. The aim of the current study was to first provide reference intervals for serum tocopherols in the adult Hungarian population with appropriate sample size, recruiting healthy control subjects and neurological patients suffering from conditions without symptoms of ataxia, myopathy or cognitive deficiency. A validated HPLC method applying a diode array detector and rac-tocol as internal standard was utilized for that purpose. Furthermore, serum cholesterol levels were determined as well for data normalization. The calculated 2.5–97.5% reference intervals for α -, β/γ - and δ -tocopherols were 24.62-54.67, 0.81-3.69 and 0.29-1.07 µM, respectively, whereas the tocopherol/cholesterol ratios were 5.11-11.27, 0.14-0.72 and 0.06-0.22 µmol/mmol, respectively. The establishment of these reference intervals may improve the diagnostic accuracy of tocopherol measurements in certain neurological conditions with decreased tocopherol levels. Moreover, the current study draws special attention to the possible pitfalls in the complex process of the determination of reference intervals as well, including the selection of study population, the application of internal standard and method validation and the calculation of tocopherol/cholesterol ratios.

KEYWORDS

cholesterol, HPLC, human samples, reference interval, tocopherol

1 | INTRODUCTION

Most of the deleterious effects of pathological processes in the 40 human organism are mediated by the formation of reactive species 41 (RS; Szalárdy, Zádori, Klivényi, Toldi, & Vécsei, 2015). The synthesis 42 and toxic effects of RS are ameliorated by a complex system of anti-43 oxidant machinery, including enzymatic (e.g. superoxide dismutase, 44 catalase and glutathione peroxidase; Sies, 1997) and nonenzymatic 45 $_{46}$ F1 mechanisms (Figure 1).

The latter group consists of numerous chemical compounds, such 47 as vitamin E, vitamin C, coenzyme Q10, β -carotene, glutathione and 48 flavonoids with proved antioxidant properties (Sies, 1993). In addition 49 to the capability of these agents to react with RS, their sufficient tissue 50 concentrations and their suitability for regeneration are desirable prop-51 erties as well for efficient antioxidant protection (Rose & Bode, 1993). 52

53 Abbreviations used: α -TTP, α -tocopherol transport protein; ACN, acetonitrile; 54 BHT, butylated hydroxy toluene; OND, other neurological disease; RI, reference interval; RS, reactive species; THF, tetrahydofurane 55

94 The vitamin E group includes four tocotrienols and four tocopherols as 95 lipid soluble antioxidants. Their molecular structure comprises a 96 chromanol ring with an aliphatic side chain, unsaturated for tocotrienols 97 and saturated for tocopherols. Depending on the number and position 98 of methyl groups on the chromanol ring, α -, β -, γ - and δ -tocotrienols 99 and tocopherols can be distinguished (Hacquebard & Carpentier, 100 2005). The bioavailability of tocotrienols is inefficient and physiological 101 serum concentrations are low (O'Byrne et al., 2000), suggesting that 102 under normal circumstances their role as antioxidants is negligible. 103 However, increasing α -tocotrienol concentration by its external supple-104 mentation can ameliorate the symptoms caused by α -tocopherol defi-105 ciency (Sen, Khanna, & Roy, 2007). α-Tocopherol has the highest 106 concentration and biological activity from the vitamin E group, while 107 the other tocopherols have a less expressed role in antioxidant protec-108 tion (Hacquebard & Carpentier, 2005). Tocopherols are taken up by the 109 enterocytes from the intestines and they are incorporated into the 110 secreted chylomicrons and transported to the liver (Cooper, 1997). In 111 the liver, the cytosolic α -tocopherol transport protein (α -TTP) 112

56 57

114

113

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

58

59




FIGURE 1 The schematic depiction of nonenzymatic mechanisms in antioxidant protection. NADPH, Reduced nicotinamide adenine dinucleotide phosphate; RS, reactive species

2 | MATERIALS AND METHODS

2.1 | Materials

14 ity of the other forms of tocopherols are rapidly excreted in the bile. α -15 TTP is responsible for the secretion of α -tocopherol into plasma and 16 very-low-density lipoprotein particles (Arita, Nomura, Arai, & Inoue, 17 1997). Very-low-density lipoprotein is catabolized on the periphery 18 by lipoprotein lipase, localized at the endothelium, and the formed 19 high-density lipoprotein and low-density lipoprotein particles become 20 responsible for the distribution of α -tocopherol to extrahepatic tissues 21 (Mardones & Rigotti, 2004). With regard to the other forms of vitamin E, 22 there is no discrimination between them and α -tocopherol during 23 absorption from the intestines: however, in the liver there is a preferen-24 tial secretion of α -tocopherol into the blood, as well as a preferential 25 metabolism of the other forms (Traber, 2013). Accordingly, cholesterol 26 levels and metabolism may considerably influence the bioavailability 27 of tocopherols (Schmölz, Birringer, Lorkowski, & Wallert, 2016).

recognizes and binds α -tocopherol with good selectivity, and the major-

13

The major causes of severe tocopherol deficiency are malabsorption disorders with decreased intestinal lipid uptake (e.g. cholestasis, cystic fibrosis, short bowel syndrome), abetalipoproteinemia and ataxia with vitamin E deficiency where the underlying pathological alteration is the decreased activity of α -TTP caused by mutations in the TTPA gene (Morley et al., 2004).

34 Decreased vitamin-E levels are associated with several neurolog-35 ical symptoms, such as cerebellar ataxia, peripheral neuropathy and 36 myopathy (Muller, 2010; Ueda et al., 2009), as the nervous system 37 is particularly sensitive to oxidative damage resulting from reduced 38 antioxidant capacity (Zádori, Klivényi, Plangár, Toldi, & Vécsei, 39 2011; Zádori et al., 2012). Accordingly, in addition to the above-40 mentioned disorders with their characteristic symptoms, some other 41 neuropsychiatric conditions, such as Alzheimer's disease (Lopes da 42 Silva et al., 2014) and the exacerbation of multiple sclerosis (Karg 43 et al., 1999) can also be accompanied by significantly reduced serum 44 or plasma tocopherol levels. Therefore, the measurement of serum 45 tocopherol levels is advised to be part of the differential diagnostic 46 process in certain neuropsychiatric conditions. The establishment of 47 unbiased reference values for the targeted population is essential 48 for that purpose.

49 The aim of the current study was to develop an unbiased 50 method for tocopherol (α -, β/γ - and δ -tocopherol) measurements 51 in human serum samples and to hereby establish reference intervals 52 (RI) via the participation of 120 individuals for the adult Hungarian 53 population based on the pooling of the values of control subjects 54 without any chronic disease and neurological patients suffering 55 from conditions without symptoms of ataxia, myopathy or cognitive 56 deficiency (the so-called control group of other neurological 57 diseases; OND).

The investigated reference compounds { α -, γ -, δ -tocopherol; (2*R*)-2,5,7,8-tetramethyl-2-[(4*R*,8*R*)-(4,8,12-trimethyltridecyl])-6-chromanol, (2*R*)-2,7,8-trimethyl-2-[(4*R*,8*R*)-4,8,12-trimethyltridecyl]-6-chromanol, (2*R*)-2,8-dimethyl-2-[(4*R*,8*R*)-4,8,12-trimethyltridecyl]-6-chromanol, respectively}, ammonium acetate, ascorbic acid {(5*R*)-[(1*S*)-1,2dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one}, butylated hydroxy toluene (BHT), dioxane and methanol were purchased from Sigma-Aldrich (Saint Louis, MO, USA), rac-tocol [2-methyl-2-(4,8,12trimethyltridecyl]-6-chromanol, as internal standard] was purchased from Matreya LLC. (Pleasant Gap, PA, USA), and acetonitrile (ACN), absolute ethanol, *n*-hexane and tetrahydofurane (THF) were purchased from VWR International (Radnar, PA, USA).

2.2 | Enrollment criteria and sample preparation

The study sample population comprised 30 male (age range 21-89 71 years, mean age 49.50 year) and 30 female volunteer individuals 90 (age range 25-76 years, mean age 50.03 year) without any major 91 chronic illness and 30 male (age range 18-73 years, mean age 92 49.43 year) and 30 female (age range 24-78 years, mean age 93 49.60 year) patients with OND (main diagnoses for males were the fol-94 lowing: ischemic stroke, 8; Parkinson's disease, 5; epilepsy, 5; lumbar 95 disk disorder, 3; and other, 9; main diagnoses for females were the fol-96 lowing: multiple sclerosis in remission, 8; ischemic stroke, 6; epilepsy, 97 5; and other, 11) where the presence of ataxia, myopathy or cognitive 98 dysfunction were excluding criteria. The distribution of the age of the 99 subjects was Gaussian in all groups (p > 0.05, Anderson–Darling test) 100 and the variances were equal (p = 0.98, Levene test). There was no sig-101 nificant difference between the groups (F = 0.01, p = 0.99, one-way 102 ANOVA). The recent regular intake of antihyperlipidemic agents or 103 any kind of drugs or food supplements containing antioxidants were 104 exclusion criteria as well in all groups. All participating individuals were 105 of Hungarian origin and were enrolled in the Department of Neurology 106 at the University of Szeged. The study was approved by the Ethics 107 Committee of the Faculty of Medicine, University of Szeged (19/ 108 2007). All study participants gave their written informed consent, in 109 accordance with the Declaration of Helsinki. 110

Blood was collected by venipuncture into gold-top vacutainers following fasting for 12 h. The blood was immediately centrifuged at 112 3500 rpm for 10 min. A 200 μ L aliquot of the supernatant serum was 113 shot into a solution containing 200 μ L ascorbic acid (0.085 M) and 114

2

3

4

5

6

7

8

9

10

11

12

13

14

15

19

20

21

22

23

24

25

50

51

52

53

stored at -80°C as well. Before high-performance liquid chromatography (HPLC) measurement, 600 μL *n*-hexane containing 1.14 mM BHT and rac-tocol as internal standard was added to the freshly thawed serum samples treated with antioxidants (800 µL). This mixture was mixed for 1 min, then centrifuged at 3500 rpm for 5 min at 4°C. The hexane layer was transferred to a test vial and evaporated under nitrogene flow. The residue was reconstituted with 75 µL ACN and 50 µL EtOH-dioxane (1:1). The resulting solution was transferred into a 200 µL glass insert placed into an amber-colored vial for measurement.

16 2.3 | Serum cholesterol and triglyceride 17 measurement 18

Total cholesterol and triglyceride levels were determined by commercially available kits from Diasys (Diagnostics Systems GmbH, Holzheim, Germany) on Roche Modular P800 analyser (Roche, Rotkreuz, Switzerland).

2.4 | Chromatographic conditions

The concentrations of α -, β/γ -, δ -tocopherol were quantified with an 26 Agilent 1200 HPLC system (Agilent Technologies, Santa Clara, CA, 27 USA) equipped with an UV/VIS diode array detector applying the mod-28 ified method of Hess, Keller, Oberlin, Bonfanti, and Schuep (1991). 29 Chromatographic separations were performed on an Alltech Prevail 30 C_{18} column, 150×4.6 mm i.d., 5 μ m particle size (Alltech Associates 31 Inc., Deerfield, IL, USA) after passage through a SecurityGuard pre-32 column, 4 × 3.0 mm i.d., 5 µm particle size (Phenomenex Inc., Torrance, 33 CA, USA) with a mobile phase composition of ACN-THF-MeOH-1% 34 w/v ammonium acetate-distilled water (684:220:68:28:28) applying 35 isocratic elution. The flow rate and the injection volume were 36 2.1 mL/min and 50 µL, respectively. The detector was set at 292 37 (α -tocopherol) and 297 (β/γ -, δ -tocopherol, rac-tocol) nm. 38

Separating β - and γ -tocopherol is challenging because they only 39 differ in the position of a methyl group. With the use of a C_{18} column 40 these two compounds have almost the same retention times (Saha, 41 Walia, Kundu, & Pathak, 2013). The β - and γ -tocopherols can only be 42 separated with the application of special columns and methods 43 (Gornas et al., 2014; Grebenstein & Frank, 2012), the application of 44 which may be challenging for routine clinical practice. Accordingly, 45 only γ -tocopherol was applied as a standard compound for the estab-46 lishment of the calibration curve in this study, and the concentration 47 at the corresponding retention time includes both substances and is 48 reported as β/γ -tocopherol. 49

2.5 | HPLC method validation for serum samples

2.5.1 | Calibration curve and linearity

54 Calibrants were prepared in six different concentration levels and 55 spiked serum samples were used with concentration ranges of 0-40, 56 0–6, 0–6 and 0–24 μ M for α -, β/γ -, δ -tocopherol and rac-tocol, respec-57 tively. The peak area responses were plotted against the

Biomedical WILEY Chromatography

corresponding concentration, and linear regression computations were

carried out by the least square method with the freely available R soft-

ware (R Development Core Team, 2002). Very good linearity

 $(R^2 \ge 0.99)$ was observed throughout the concentration ranges for α -,

3 of 8

58 59 60

66

67

68

69

70

71

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

2.5.2 | Selectivity

 β/γ -, δ -tocopherol and rac-tocol.

The selectivity of the method was checked by comparing the chromatograms of α -, β/γ -, δ -tocopherol and rac-tocol for a blank serum sample and those for a spiked sample. All compounds could be detected in their own selected chromatograms without any significant **F2**₇₂ interference, as can be seen in Figure 2.

2.5.3 | Precision

For the determination of within-run precision five samples for four concentration levels were applied (i.e., 20 replicates altogether). This study was repeated two more times with at least one week intervals to obtain between-run precision. With regard to within-run precision the coefficients of variation of the measured concentrations were 4.53, 3.72 and 5.11% for α -, β/γ - and δ -tocopherols, respectively, whereas in case of between-run precision, they were 3.59, 5.93 and 4.76% for α -, β/γ - and δ -tocopherol, respectively.

2.5.4 Recovery

The relative recoveries were estimated by measuring spiked samples of α -, β/γ - and δ -tocopherol at two different concentrations with three replicates of each. No significant differences were observed for the lower and higher concentrations. The recoveries for the serum samples ranged from 86 to 105%, from 95 to 108% and from 116 to 124% for α -, β/γ - and δ -tocopherol, respectively.




FIGURE 2 The representative chromatograms of tocopherol measurement. The gray line represents a blank serum sample which was spiked with a mixture containing rac-tocol (1), α -tocopherol (2), γ tocopherol (4) and δ -tocopherol (3) (black line). The peak spiked with γ tocopherol may contain β -tocopherol from the blank serum as well

RØ

2.6 | Statistics

4 of 8

All statistical calculations were performed with the use of the freely available R software (R Development Core Team, 2002) according to the International Federation of Clinical Chemistry and Laboratory Medicine and Clinical and Laboratory Standards Institute guidelines (Horowitz, 2016). Based on these guidelines, the minimum required number of individuals for the determination of RI with the bootstrap method is at least 100. First we checked the distribution of our data with the Anderson-Darling test and we also performed the Levene test for analysis of the homogeneity of variances. If the distribution proved to be Gaussian and the variances were equal, one-way ANOVA was applied to compare the groups, otherwise the Kruskal-Wallis test was utilized. To obtain the necessary quantiles and their confidence intervals for the determination of the reference intervals, the bootstrap method (1000 iterations) was applied. The correlation between the concentration of the measured compounds and the age of individuals in the sample population was examined with the nonparametric Spearman's test. We rejected the null hypothesis when the corrected *p*-values were ≤0.05, and in such cases the differences were considered significant. Data with Gaussian or non-Gaussian distributions were plotted as means (\pm SD) or medians (and interquartile range), respectively.

3 | RESULTS

The group-wise comparisons failed to detect any significant difference between groups regarding the concentrations of α -tocopherol $(p = 0.48, \chi^2 = 2.46;$ Kruskal-Wallis test), β/γ -tocopherol $(p = 0.47, \chi^2)$

 $x^2 = 2.53$: Kruskal-Wallis test) or δ -tocopherol (p = 0.82, $x^2 = 0.94$; Kruskal-Wallis test; Table 1).

Accordingly, in order to establish RI with appropriate subject numbers, the values for each measured compounds were pooled and the minimum required sample size (n = 120) was achieved. For the determination of lower (2.5%) and upper (97.5%) RI with the corresponding confidence intervals and standard errors, the bootstrap method was applied and the results are demonstrated in Table 2.

To obtain cholesterol-corrected tocopherol values as well, serum cholesterol concentrations were determined for each subject [median and interquartile range 4.99 mM (4.31-5.54)] and the tocopherol/cholesterol ratios were calculated. The bootstrap method was applied again for the lipid corrected values (Table 3). **T**3 To assess the incidental effect of age on measured serum lipid levels, the Spearman test was performed. The cholesterol levels positively correlated with the age of subjects (p < 0.001, Spearman's $\rho = 0.34$; Figure 3). F3

In the case of uncorrected α - and β/γ -tocopherol concentrations, this correlation with age is present as well (α -tocopherol: p = 0.002. Spearman's $\rho = 0.28$. Figure 4A: β/γ -tocopherol: p = 0.001, Spearman's $\rho = 0.29$, Figure 4C) whereas δ -tocopherol levels did not correlate with age (p = 0.98, Spearman's ρ = 0.003, Figure 4E). When tocopherol levels were normalized to cholesterol levels, all the correlations with age were eliminated (a-tocopherol: p = 0.99, Spearman's $\rho = -0.0007$, Figure 4B; β/γ tocopherol: p = 0.14, Spearman's $\rho = 0.14$, Figure 4D; δ -tocopherol: $\rho = 0.051$, Spearman's $\rho = -0.18$, Figure 4F).

TABLE 1 Serum tocopherol concentrations of subjects belonging to the control and OND groups

	Controls (women)	Controls (men)	OND patients (women)	OND patients (men)	Group comparisons (p)
α-Tocopherol (μм)	38.08 (33.70-44.10)	35.38 (31.35-45.83)	34.26 (29.40-41.60)	33.93 (30.54-41.08)	0.48 ($\chi^2 = 2.46$)
β/γ -Tocopherol (μ M)	1.83 (1.32-2.23)	1.68 (1.39-2.52)	1.57 (1.33-1.82)	1.75 (1.52-2.21)	$0.47 (\chi^2 = 2.53)$
δ-Tocopherol (μ M)	0.63 (0.52-0.86)	0.62 (0.53-0.78)	0.62 (0.55-0.82)	0.65 (0.57-0.75)	0.82 ($\chi^2 = 0.94$)

Group-wise comparisons (Kruskal-Wallis test) of the four groups failed to detect any significant difference between serum tocopherol levels. Data are presented as median and interquartile range. OND, Other neurological disease.

TABLE 2 The calculated uncorrected lower (2.5%) and upper (97.5%) reference intervals for tocopherols for the assessed Hungarian population (n = 120)

	2.5%	SE	CI (95%)	97.5%	SE	CI (95%)
α-Tocopherol (μм)	24.62	0.76	23.24-26.26	54.67	4.09	46.88-61.84
$β/\gamma$ -Tocopherol (μM)	0.81	0.13	0.60-1.11	3.69	0.45	2.71-4.55
δ-Tocopherol (μм)	0.29	0.03	0.22-0.32	1.07	0.13	0.80-1.29

SE, Standard error; CI, confidence interval.

TABLE 3 The calculated cholesterol corrected lower (2.5%) and upper (97.5%) reference intervals for tocopherols for the assessed Hungarian population (n = 120)

	2.5%	SE	CI (95%)	97.5%	SE	CI (95%)
α-Tocopherol (µmol/mmol)	5.11	0.14	4.79-5.36	11.27	0.69	9.91-12.82
β/γ -Tocopherol (µmol/mmol)	0.14	0.02	0.10-0.19	0.72	0.07	0.60-0.88
δ-Tocopherol (µmol/mmol)	0.06	0.01	0.05-0.07	0.22	0.03	0.16-0.27






FIGURE 3 Serum cholesterol concentrations in function of age. There is a positive correlation between cholesterol levels and age (p < 0.001, Spearman's $\rho = 0.34$)

5 of 8

4 | DISCUSSION

The determination of exact serum tocopherol concentrations may be substantial for the diagnosis and therapeutic monitoring of certain conditions usually accompanied by neurological symptoms, such as ataxia, myopathy or cognitive deficiency (La Fata, Weber, & Mohajeri, 2014; Muller, 2010). Although the symptoms of genetically determined disorders with tocopherol deficiency usually manifest during childhood (Raizman et al., 2014), malabsorption disorders and late-onset genetically determined metabolic conditions preferentially appear in adulthood, indicating the need for tocopherol measurement in adult population as well (Ueda et al., 2009). However, these concentrations alone hold little diagnostic value, for proper evaluation physicians need a well-established RI, which can considerably vary between populations (Table S1 in the Supporting Information). The underlying cause of this variation may be multifactorial, mainly including nonstandardized patient selection criteria and some methodological issues. The




FIGURE 4 Serum tocopherol concentrations and tocopherol/cholesterol ratios plotted against the age of participants. The level of α -tocopherol positively correlates with age (p = 0.002, Spearman's $\rho = 0.28$; A), similarly to β/γ -tocopherol (p = 0.001, Spearman's $\rho = 0.29$; C), whereas δ -tocopherol levels do not correlate with age (p = 0.98, Spearman's $\rho = 0.003$; E). The cholesterol corrected values of α -tocopherol (p = 0.99, Spearman's $\rho = 0.003$; E). The cholesterol corrected values of α -tocopherol (p = 0.99, Spearman's $\rho = 0.14$; D) do not further significantly correlate with age, and the correlation of δ -tocopherol levels with age also remained nonsignificant (p = 0.051, Spearman's $\rho = -0.18$; F)

62

63

64

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

6 of 8 WILEY Biomedical Chromatography

1

aim of the current study was to establish RIs for the Hungarian population and to compare the method of patient selection and the analytical procedure with those of previously published studies.

6 The investigated population in this study is homogeneously dis-7 tributed with regard to age and covers a considerably wide age range 8 for the adult population. The selection of a homogeneous study popu-9 lation may have a special importance, because age distribution can 10 considerably influence reference values in light of the fact that the levels of certain tocopherols significantly increase with age (Figure 4: 11 12 Rifkind & Segal, 1983). Accordingly when the investigated reference 13 population includes young individuals, the results may be skewed to 14 lower levels (Ford, Schleicher, Mokdad, Ajani, & Liu, 2006; Paliakov 15 et al., 2009: Quesada, Mata-Granados, & Lugue De Castro, 2004: 16 Zhao, Monahan, McNulty, Gibney, & Gibney, 2014). Moving on to 17 another gualitative aspect of the composition of the study population. 18 in addition to the involvement of subjects without any chronic illness. 19 the group of assessed individuals also comprised patients with differ-20 ent neurological disorders where tocopherol levels were not previously 21 reported to be abnormal (the establishment of the so-called control 22 group of OND). This study setup may ensure the absence of significant 23 alterations of tocopherol levels in neurological cases lacking the symp-24 toms of ataxia, myopathy and cognitive deficiency, which may be 25 important for future screening studies. Following thorough statistical 26 assessment resulting in the lack of significant differences, these sub-27 groups become suitable for pooling, i.e. the number of individuals in 28 the reference population can be increased easily to the desired level. 29 Several previous studies lack this study setup including well-detailed 30 description of the health condition of reference individuals, possibly 31 introducing a bias into the reference values (Table S1; Paliakov et al., 32 2009; Quesada et al., 2004). In the current study design, special atten-33 tion was paid to dietary factors and to the intake of special medicines 34 (e.g. statins) and food supplements as well, because these may consid-35 erably alter the levels of the assessed compounds (Colquhoun et al., 36 2005). The lack of this kind of standardization introduces another bias 37 into the establishment of RIs (Table S1; Winbauer, Pingree, & Nuttall, 38 1999: Yuan et al., 2014).

39 With regard to the analytical procedure of the determination of 40 tocopherol concentrations from biological matrices, several difficul-41 ties can emerge as well. While the use of serum or heparinized 42 plasma for measurement does not affect α -tocopherol level (Table 43 S1), the application of oxalate, citrate or ethylenediaminetetraacetic 44 acid significantly reduces its concentration (Nierenberg & Lester, 45 1985). The most problematic step in the measurement process may 46 be the sample preparation, which includes liquid-liquid extraction 47 into *n*-hexane, evaporation under nitrogen flow and reconstitution 48 in organic solvents. The emerging problems during these steps and 49 during sample injection can considerably contribute to the overall 50 error of the measurement. Internal standards in known quantity 51 can be utilized to compensate for the bias between the measured 52 and true concentrations. In the current study, rac-tocol was applied 53 as internal standard, but several other compounds can be utilized 54 (Table S1).

55 Another important matter may be the validation of the applied 56 analytical procedure, which can provide valuable information about 57 the robustness of the measurement and the validity of the reported values. For scientific publications at least a partial method validation is required (ICH, 1995). Without method validation the reliability of the presented data is questionable. Approximately 80% of the previous studies presenting human tocopherol concentrations applied a validation procedure (Table S1).

Tocopherol levels are often reported as tocopherol-cholesterol 65 ratios based on the fact that there is a close relationship between 66 the concentrations of tocopherols and lipids in the blood (Thurnham, 67 Davies, Crump, Situnavake, & Davis, 1986), However, under special 68 circumstances lipid-corrected tocopherol levels can be misleading, 69 because it was reported that malnutrition and infectious diseases in 70 children can lower the levels of circulating cholesterol and its lipopro-71 tein carriers, which alteration can mask decreased tocopherol levels if 72 only corrected values are reported (Das, Thurnham, & Das, 1996; 73 Sauerwein et al., 1997: Squali Houssaïni et al., 2001). Contrarily, when 74 obese children were investigated, their α -tocopherol levels were nor-75 mal while their tocopherol-cholesterol ratios were significantly lower 76 compared with the control group (Strauss, 1999). With regard to 77 adults, in light of the fact that lipid status can vary with aging 78 79 (Figure 3; Rifkind & Segal, 1983), the application of lipid-corrected values may be necessary for the characterization of vitamin E status 80 (Horwitt, Harvey, Dahm, & Searcy, 1972; Thurnham et al., 1986). 81 Nevertheless, the report of serum tocopherol concentrations with lipid 82 ratios may be practical for the proper evaluation of tocopherol status. 83 However, only one-third of the papers reported both of them 84 85 (Table S1 in the Supporting Information).

In conclusion, the current study presents RIs for the first time for serum tocopherol concentrations and their corresponding cholesterol corrected values with regard to the adult Hungarian population. These results can facilitate the diagnostic process for certain neurological conditions, such as ataxia with vitamin E deficiency. Moreover, this paper draws attention to the importance of thorough design associated with the establishment of these RIs and the possible pitfalls in tocopherol measurements.

ACKNOWLEDGEMENTS

The authors are grateful to Péter Monostori and Eszter Karg (Department of Pediatrics, University of Szeged, Szeged, Hungary) for their valuable advice during method development. Furthermore, we would like to thank Adrienn Szabó-Laboda (Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged) and Edina Cseh (Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged and Babeş-Bolyai University, Faculty of Chemistry and Chemical Engineering, Cluj-Napoca) for their assistance during the measurements. This research was supported by the Hungarian Brain Research Program – grant no. KTIA_13_NAP-A_II/18. Dr Dénes Zádori was supported by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences.

DISCLOSURE OF INTEREST

The authors report no conflict of interest.

Biomedical Chromatography 7 of 8 WILEY REFERENCES Nierenberg, D. W., & Lester, D. C. (1985). Determination of vitamins A and E in serum and plasma using a simplified clarification method and high-Arita, M., Nomura, K., Arai, H., & Inoue, K. (1997). Alpha-tocopherol transperformance liquid chromatography. Journal of Chromatography, 345, fer protein stimulates the secretion of alpha-tocopherol from a cultured 275 - 284liver cell line through a brefeldin A-insensitive pathway. Proceedings of the National Academy of Sciences of the United States of America, 94. O'Byrne, D., Grundy, S., Packer, L., Devaraj, S., Baldenius, K., Hoppe, P. P., ... Traber, M. G. (2000). Studies of LDL oxidation following alpha-, 12437-12441. gamma-, or delta-tocotrienyl acetate supplementation of hypercholes-Colquhoun, D. M., Jackson, R., Walters, M., Hicks, B. J., Goldsmith, J., terolemic humans. Free Radical Biology and Medicine, 29, 834-845. Young, P., ... Kostner, K. M. (2005). Effects of simvastatin on blood Paliakov, E. M., Crow, B. S., Bishop, M. J., Norton, D., George, J., & Bralley, J. A. lipids, vitamin E, coenzyme Q 10 levels and left ventricular function in 10 humans. European Journal of Clinical Investigation, 35, 251-258. (2009). Rapid quantitative determination of fat-soluble vitamins and 11 coenzyme O-10 in human serum by reversed phase ultra-high Cooper, A. D. (1997). Hepatic uptake of chylomicron remnants. Journal of 12 pressure liquid chromatography with UV detection. Journal of Chroma-Lipid Research, 38, 2173-2192. tography B: Analytical Technologies in the Biomedical and Life Sciences, 13 Das, B. S., Thurnham, D. I., & Das, D. B. (1996). Plasma alpha-tocopherol, 877, 89-94. 14 retinol, and carotenoids in children with falciparum malaria. The Ameri-Quesada, J. M., Mata-Granados, J. M., & Lugue De Castro, M. D. (2004). 15 can Journal of Clinical Nutrition, 64, 94-100. Automated method for the determination of fat-soluble vitamins in 16 Ford, E. S., Schleicher, R. L., Mokdad, A. H., Ajani, U. A., & Liu, S. (2006). serum. Journal of Steroid Biochemistry and Molecular Biology, 89-90, Distribution of serum concentrations of alpha-tocopherol and gamma-473-477. 17 tocopherol in the US population. The American Journal of Clinical R Development Core Team. The R Project for Statistical Computing. Text 18 Nutrition, 84, 375-383. 1-9. R Foundation for Statistical Computing, 2002. Available from: 19 Gornas, P., Siger, A., Czubinski, J., Dwiecki, K., Seglina, D., & Nogalahttp://www.r-project.org/ 20 Kalucka, M. (2014). An alternative RP-HPLC method for the separa-Raizman, J. E., Cohen, A. H., Teodoro-Morrison, T., Wan, B., Khun-Chen, 21 tion and determination of tocopherol and tocotrienol homologues as M., Wilkenson, C., ... Adeli, K. (2014). Pediatric reference value distribubutter authenticity markers: A comparative study between two Euro-22 tions for vitamins a and E in the CALIPER cohort and establishment of pean countries. European Journal of Lipid Science and Technology, 116, age-stratified reference intervals. Clinical Biochemistry, 47, 812-815. 23 895-903. Rifkind, B. M., & Segal, P. (1983). Lipid research clinics program reference 24 Grebenstein, N., & Frank, J. (2012). Rapid baseline-separation of all eight values for hyperlipidemia and hypolipidemia. JAMA, 250, 1869-1872. 25 tocopherols and tocotrienols by reversed-phase liquid-chromatography Rose, R. C., & Bode, A. M. (1993). Biology of free radical scavengers: An with a solid-core pentafluorophenyl column and their sensitive quanti-26 evaluation of ascorbate. FASEB Journal: Official Publication of the Federfication in plasma and liver. Journal of Chromatography A, 1243, 39-46. 27 ation of American Societies for Experimental Biology, 7, 1135–1142. Hacquebard, M., & Carpentier, Y. A. (2005). Vitamin E: Absorption, plasma 28 Saha, S., Walia, S., Kundu, A., & Pathak, N. (2013). Effect of mobile phase on transport and cell uptake. Current Opinion in Clinical Nutrition and Met-29 resolution of the isomers and homologues of tocopherols on a abolic Care. 8, 133-138. triacontyl stationary phase. Analytical and Bioanalytical Chemistry, 405, 30 Hess, D., Keller, H. E., Oberlin, B., Bonfanti, R., & Schuep, W. (1991). Simul-9285-9295 31 taneous determination of retinol, tocopherols, carotenes and lycopene Sauerwein, R. W., Mulder, J. A., Mulder, L., Lowe, B., Peshu, N., Demacker, 32 in plasma by means of high performance liquid chromatography on P. N., ... Marsh, K. (1997). Inflammatory mediators in children with proreversed phase. International Journal for Vitamin and Nutrition Research, 33 tein-energy malnutrition. The American Journal of Clinical Nutrition, 65, 61.232-238. 1534-1539. 34 Horowitz, G. L. (2016). Establishment and use of reference values. In Tietz Schmölz, L., Birringer, M., Lorkowski, S., & Wallert, M. (2016). Complexity 35 Textbook of Clinical Chemistry and Molecular Diagnostics (5th ed.)). of vitamin E metabolism. World Journal of Biological Chemistry, 7, 14-43. 36 Oxford: Elsevier chapter 5. Sen, C. K., Khanna, S., & Roy, S. (2007). Tocotrienols in health and disease: 37 Horwitt, M. K., Harvey, C. C., Dahm, C. H., & Searcy, M. T. (1972). Relation-The other half of the natural vitamin E family. Molecular Aspects of Medship between tocopherol and serum lipid levels for determination of 38 icine. 28. 692-728. nutritional adequacy. Annals of the New York Academy of Sciences, 39 Sies, H. (1993). Strategies of antioxidant defense. European Journal of Bio-203, 223-236. 40 chemistry, 215, 213-219. ICH (1995). ICH Harmonized tripartite guideline, validation of analytical 41 Sies, H. (1997). Oxidative stress: Oxidants and antioxidants. Experimental procedures. Federal Register, 60, 11260. Physiology, 82, 291-295. 42 Karg, E., Klivényi, P., Németh, I., Bencsik, K., Pintér, S., & Vécsei, L. (1999). Squali Houssaïni, F. Z., Foulon, T., Payen, N., Iraqi, M. R., Arnaud, J., & 43 Nonenzymatic antioxidants of blood in multiple sclerosis. Journal of Groslambert, P. (2001). Plasma fatty acid status in Moroccan children: Neurology, 246, 533-539. 44 Increased lipid peroxidation and impaired polyunsaturated fatty acid 45 La Fata, G., Weber, P., & Mohajeri, M. H. (2014). Effects of vitamin E on metabolism in protein-calorie malnutrition. Biomedicine and Pharmacocognitive performance during ageing and in Alzheimer's disease. Nutritherapy, 55, 155-152. 46 ents. 6. 5453-5472. 47 Strauss, R. S. (1999). Comparison of serum concentrations of α -tocopherol Lopes da Silva, S., Vellas, B., Elemans, S., Luchsinger, J., Kamphuis, P., Yaffe, and β -carotene in a cross-sectional sample of obese and nonobese chil-48 K., ... Stijnen, T. (2014). Plasma nutrient status of patients with dren (NHANES III). The Journal of Pediatrics, 134, 160-165. 49 Alzheimer's disease: Systematic review and meta-analysis. Alzheimer's Szalárdy, L., Zádori, D., Klivényi, P., Toldi, J., & Vécsei, L. (2015). Electron and Dementia, 10, 485-502. 50 transport disturbances and neurodegeneration: From Albert Szent-51 Mardones, P., & Rigotti, A. (2004). Cellular mechanisms of vitamin E uptake: Györgyi's concept (Szeged) till novel approaches to boost mitochondrial Relevance in alpha-tocopherol metabolism and potential implications bioenergetics. Oxidative Medicine and Cellular Longevity, 498401. 52 for disease. Journal of Nutritional Biochemistry, 15, 252-260. Thurnham, D. I., Davies, J. A., Crump, B. J., Situnayake, R. D., & Davis, M. 53 Morley, S., Panagabko, C., Shineman, D., Mani, B., Stocker, A., Atkinson, J., (1986). The use of different lipids to express serum tocopherol: Lipid 54 & Manor, D. (2004). Molecular determinants of heritable vitamin E defiratios for the measurement of vitamin E status. Annals of Clinical Bio-55 ciency. Biochemistry, 43, 4143-4149. chemistry, 23, 514-520. 56 Muller, D. P. R. (2010). Vitamin E and neurological function. Molecular Traber, M. G. (2013). Mechanisms for the prevention of vitamin E excess. 57 Nutrition and Food Research, 54, 710-718. Journal of Lipid Research, 54, 2295-2306.

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

VERES FT AL.

1

2

3

4

5

6

7

8

9

1 2	8 of 8 WILEY-Biomedical Chromatography	VERES ET AL. 58	
2 3 4 5	Ueda, N., Suzuki, Y., Rino, Y., Takahashi, T., Imada, T., Takanashi, Y., & Kuroiwa, Y. (2009). Correlation between neurological dysfunction with vitamin E deficiency and gastrectomy. <i>Journal of the Neurological Sci-</i> <i>ences</i> , 287, 216–220.	Zhao, Y., Monahan, F. J., McNulty, B. A., Gibney, M. J., & Gibney, E. R. (2014). Effect of vitamin E intake from food and supplement sources on plasma α - and γ -tocopherol concentrations in a healthy Irish adult population. <i>The British Journal of Nutrition</i> , 112, 1575–1585.	0 1 2
6 7	Winbauer, A. N., Pingree, S. S., & Nuttall, K. L. (1999). Evaluating serum alpha-tocopherol (vitamin E) in terms of a lipid ratio. <i>Annals of Clinical</i>	63	
8	and Laboratory Science, 29, 185–191.	SUPPORTING INFORMATION 65	ō
9	Yuan, C., Burgyan, M., Bunch, D. R., Reineks, E., Jackson, R., Steinle, R., &	Additional Supporting Information may be found online in the 66	5
10	Wang, S. (2014). Fast, simple, and sensitive high-performance liquid chromatography method for measuring vitamins a and E in human	supporting information tab for this article. 67	7
11	blood plasma. Journal of Separation Science, 37, 2293–2299.	68	3
12	Zádori, D., Klivényi, P., Plangár, I., Toldi, J., & Vécsei, L. (2011). Endogenous	How to cite this article: Veres G, Szpisjak L, Bajtai A, et al.	
13	neuroprotection in chronic neurodegenerative disorders: With particu- lar regard to the kynurenines. Journal of Cellular and Molecular Medicine,	The establishment of tocopherol reference intervals for	
14	15, 701–717.	Hungarian adult nonulation using a validated HPLC method	
15	Zádori, D., Klivényi, P., Szalárdy, L., Fülöp, F., Toldi, J., & Vécsei, L. (2012).	Biomedical Chromatography. 2017;e3953. https://doi.org/	
16 17	Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: Novel therapeutic strategies for neurodegenerative disor-	10.1002/bmc.3953	
18	ders. Journal of the Neurological Sciences, 322, 187–191.	75	
19		76	
20		77	
21		78	3
22		75	9
23		80	С
24		81	1
25		82	2
26		83	
27		84	
28 29		85	
30	C	87	
31		88	
32		82 83 84 85 86 87 87 88 87 88 89 90	
33		90)
34		91	1
35		92	
36		93	
37 38		94 95	
30 39		96	
40		97	
41		98	
42		99	9
43		10	00
44		10	
45		10	
46		10	
47 40		10	
48 49		10	
50		10	
51		10	
52		10	
53		11	10
54		11	
55		11	
56		11	
57		11	14

Journal: Biomedical Chromatography

Article: bmc_3953

Dear Author,

During the copyediting of your paper, the following queries arose. Please respond to these by annotating your proofs with the necessary changes/additions.

- If you intend to annotate your proof electronically, please refer to the E-annotation guidelines.
- If you intend to annotate your proof by means of hard-copy mark-up, please use the standard proofing marks. If manually writing corrections on your proof and returning it by fax, do not write too close to the edge of the paper. Please remember that illegible mark-ups may delay publication.

Whether you opt for hard-copy or electronic annotation of your proofs, we recommend that you provide additional clarification of answers to queries by entering your answers on the query sheet, in addition to the text mark-up.

Query No.	Query	Remark
Q1	AUTHOR: Please check the captured given names and family names are	
Q2	AUTHOR: Please verify that the linked ORCID identifiers are correct for each author.	